XT
MTNB icon

XTX Topco’s Matinas BioPharma MTNB Stock Holding History

XTX Topco’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,706
Closed -$10.4K – 4516
2026
Q1 		$10.4K Buy
20,706
+3,797
+22% +$2.38K ﹤0.01% 3680
2025
Q4 		$9.91K Buy
+16,909
New +$19.9K ﹤0.01% 3184
2024
Q1 		– Sell
-1,523
Closed -$16.5K – 2151
2023
Q4 		$16.5K Buy
1,523
+845
+125% +$9.54K ﹤0.01% 1384
2023
Q3 		$4.41K Buy
+678
New +$8.33K ﹤0.01% 1470

Other funds holding MTNB

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HIW
Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

XTX Topco's MTNB Position: Q2 2026 in Review

XTX Topco sold out of Matinas BioPharma (MTNB) in Q2 2026, closing a stake of 20,706 shares — an estimated $10.4K sold.

XTX Topco first reported a position in MTNB in Q3 2023 and held it in 4 quarters. The position peaked at $16.5K in Q4 2023. 25 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.

  • XTX Topco reported no remaining Matinas BioPharma position as of Q2 2026 after selling out during the quarter.
  • XTX Topco sold 20,706 Matinas BioPharma shares in Q2 2026, an estimated $10.4K.
  • XTX Topco first reported a position in Matinas BioPharma in Q3 2023 and held it in 4 quarters.
  • XTX Topco's Matinas BioPharma position peaked at $16.5K in Q4 2023.
  • 25 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.